SCHEMBL1604211

SCHEMBL1604211

Cc1sc2ncnc(NC3CCN(Cc4ccccc4C#N)CC3)c2c1C

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.71
KMT2A Q03164 4/20 0.71
HTT P42858 3/20 0.71
RAB9A P51151 2/20 0.71
RXFP1 Q9HBX9 2/20 0.71
SMN1; SMN2 Q16637 2/20 0.71
MAPK1 P28482 2/20 0.71
LMNA P02545 1/20 0.51
NOD2 Q9HC29 1/20 0.51
IRAK4 Q9NWZ3 1/20 0.50
HTR2B P41595 1/20 0.46
ACHE P22303 1/20 0.45
DRD4 P21917 1/20 0.43
JAK1 P23458 3/20 0.43
TYK2 P29597 3/20 0.43
JAK2 O60674 1/20 0.43
MAPT P10636 2/20 0.43
HPGD P15428 1/20 0.43
JAK3 P52333 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1604752 0.91 MEN1 (0.61) MEN1KMT2AHTTRAB9ARXFP1
SCHEMBL12790000 0.83 MEN1 (1.00) MEN1KMT2AHTTRAB9ARXFP1
SCHEMBL12710494 0.83 MEN1 (0.71) MEN1KMT2AHTTRAB9ARXFP1
SCHEMBL12533520 0.78 MEN1 (0.66) MEN1KMT2AHTTRAB9ARXFP1
SCHEMBL21458102 0.78 MEN1 (0.88) MEN1KMT2AHTTRAB9ARXFP1
SCHEMBL21458101 0.78 MEN1 (0.88) MEN1KMT2AHTTRAB9ARXFP1
SCHEMBL21458104 0.78 MEN1 (0.88) MEN1KMT2AHTTRAB9ARXFP1
SCHEMBL1604774 0.75 MEN1 (0.62) MEN1KMT2AHTTRAB9ARXFP1
SCHEMBL12710348 0.75 MEN1 (0.61) MEN1KMT2AHTTRAB9ARXFP1
SCHEMBL1604969 0.74 SMN1; SMN2 (0.66) MEN1KMT2AHTTRAB9ARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1622914-B1 NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS TROVIS PHARMACEUTICALS LLC (US) 2011-06-01 EP disclosed
EP-1622914-B1 NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS TROVIS PHARMACEUTICALS LLC (US) 2011-06-01 EP disclosed
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2011-04-07 US disclosed
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2011-04-07 US disclosed
US-20100280050-A1 Piperidinylamino-Thieno[2,3-D] Pyrimidine Compounds for Treating Fibrosis PGXHEALTH, LLC 2010-11-04 US disclosed
EP-1797099-B1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS EPIX DELAWARE INC (US) 2010-08-11 EP disclosed
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2010-05-06 US disclosed
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2010-05-06 US disclosed
US-7612078-B2 Piperidinylamino-thieno[2,3-D] pyrimidine compounds EPIX DELAWARE, INC. (US) 2009-11-03 US disclosed
US-7612078-B2 Piperidinylamino-thieno[2,3-D] pyrimidine compounds EPIX DELAWARE, INC. (US) 2009-11-03 US disclosed
WO-2009032885-A2 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS FOR TREATING FIBROSIS EPIX DELAWARE, INC. (US) 2009-03-12 WO disclosed
US-20050222176-A1 Piperidinylamino-thieno[2,3-D] pyrimidine compounds TROVIS PHARMACEUTICALS, LLC 2005-10-06 US disclosed
US-20050222175-A1 New piperidinylamino-thieno[2,3-D] pyrimidine compounds PGXHEALTH, LLC 2005-10-06 US disclosed
US-20040248904-A1 New piperidinylamino-thieno[2,3-d] pyrimidine compounds TROVIS PHARMACEUTICALS, LLC 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280050-A1 Piperidinylamino-Thieno[2,3-D] Pyrimidine Compounds for Treating Fibrosis HTR2B, HTR3B, HTR1B MEN1 4310/4885KMT2A 2743/4885HTT 2183/4885
US-20050222175-A1 New piperidinylamino-thieno[2,3-D] pyrimidine compounds HTR5A, HTR3A, HTR1A MEN1 2389/4885KMT2A 4258/4885HTT 3169/4885
US-20040248904-A1 New piperidinylamino-thieno[2,3-d] pyrimidine compounds HTR5A, HTR2C, HTR1A MEN1 2833/4885KMT2A 3770/4885HTT 1773/4885
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds HTR2B, HTR3B, HTR1B MEN1 4118/4885KMT2A 3047/4885HTT 2061/4885
US-20050222176-A1 Piperidinylamino-thieno[2,3-D] pyrimidine compounds HTR2B, HTR3B, HTR1B MEN1 4118/4885KMT2A 3047/4885HTT 2061/4885
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds HTR5A, HTR3A, HTR1A MEN1 2784/4885KMT2A 4320/4885HTT 3083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.